12/8/2015 | PP | Pozen amends debt facility, subscription agreement with Deerfield
|
10/30/2015 | PP | Pozen changes issuer of upcoming notes, gets option to sell for cash
|
6/8/2015 | BK | Pozen lines up $200 million senior secured facility for acquisition
|
6/8/2015 | PP | Pozen negotiates $150 million private placement of stock, convertibles
|
3/26/2008 | SP | New Issue: JPMorgan prices $575,000 27.5% reverse exchangeables linked to Pozen
|
8/9/2007 | SP | New Issue: HSBC sells $600,000 of 25% reverse convertibles linked to Pozen
|
11/10/2006 | BT | Market Commentary: Tanox soars 45% on Genentech buy; Targeted Genetics adds 26%, Pozen higher; Insmed, Tercica better
|
11/7/2006 | BT | Pozen confident Trexima will be approved in 2007
|
11/1/2006 | BT | RBC ups Pozen price target to $20
|
10/31/2006 | BT | Pozen reports $4.1 million net loss for third quarter, revenue up to $3.4 million
|
9/26/2006 | BT | RBC rates Pozen at outperform
|
9/22/2006 | BT | Pozen at outperform by RBC
|
9/21/2006 | BT | Market Commentary: Nycomed deal seen coming on Altana buy; Warner Chilcott slips on debut; Serono up on buyout
|
9/21/2006 | BT | Pozen gets $40 million payment from AstraZeneca, revises outlook
|
9/20/2006 | BT | GlaxoSmithKline, Pozen say Trexima offers consistent migraine relief
|
9/19/2006 | BT | Pozen kept at outperform by RBC
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/4/2006 | BT | Pozen rated at outperform by RBC
|
8/4/2006 | BT | Pozen rated at outperform by RBC
|
8/3/2006 | BT | Pozen rated outperform by RBC
|
8/2/2006 | BT | Pozen rated at outperform by RBC
|
8/2/2006 | BT | Pozen rated at outperform by RBC
|
8/2/2006 | BT | Market Commentary: Pozen pumped by partnership; Biovail battered by patent loss; Gene Logic gains on layoffs
|
8/2/2006 | BT | Pozen, AstraZeneca to develop combination pain reliever
|
7/31/2006 | BT | Pozen plans response to FDA approvable letter for migraine treatment Trexima
|
7/31/2006 | BT | RBC reiterates Pozen at outperform
|
7/31/2006 | BT | Market Commentary: ImClone off 4%, Repligen soars; Viragen slides, Napo debuts up; Pozen gains; Novavax up 12.5%
|
7/27/2006 | BT | Pozen former employee, friend agree to settlement with SEC over insider trading allegations
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/26/2006 | BT | GlaxoSmithKline, Pozen: sumatriptan effective in treating head and neck pain associated with migraines
|
6/12/2006 | BT | Pozen at outperform by RBC
|
6/12/2006 | BT | Market Commentary: NPS Pharma drops 19% to new low; Avigen up; CV Therapeutics drops 5%; Pozen pushed up 11%
|
6/9/2006 | BT | Pozen, Glaxo may conduct more studies of investigational migraine treatment Trexima
|
6/9/2006 | BT | Market Commentary: Pozen plunges after FDA setback; NxStage climbs after follow-on; BioNumerik nixes IPO plans
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
4/20/2006 | BT | Pozen plans trial of PN 200 for arthritis
|
4/5/2006 | BT | GlaxoSmithKline, Pozen say one tablet combats vascular, neurological causes of migraine
|
3/1/2006 | BT | Pozen says $20 million milestone payment contributes to profitability
|
1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
11/28/2005 | BT | Pozen receives first regulatory approval; MT 100 given go-ahead for migraine in U.K.
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/2/2005 | BT | Pozen's PN 100 reduces gastric damage caused by anti-inflammatory drugs, study finds
|